TheraRadar
Data updated: May 26, 2026

ZECUITY (sumatriptan succinate)

CNS Approved 2013-01-17
1
Indication
--
Phase 3 Trials
13
Years on Market

Details

Status
Discontinued
First Approved
2013-01-17
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
IONTOPHORESIS
Dosage Forms
SYSTEM

Companies

Active Ingredient: SUMATRIPTAN SUCCINATE

ZECUITY Approval History

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
7 FDA actions from 2013 to 2015
Aug 2015 SUPPL
Mfg · Manufacturing (CMC)
Apr 2015 SUPPL
Mfg · Manufacturing (CMC)
Mar 2015 SUPPL
Mfg · Manufacturing (CMC)

What ZECUITY Treats

1 FDA approvals

Originally approved for its first indication in 2013 .

  • Other (1)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT01381796 PROT-15-NP101-013 Ph 1 completed Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults
NCT00723983 NP101-011 PROT-15-NP101-011 Ph 1 completed Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
NCT00920686 results posted NXN-188-203 Ph 2 completed Study of NXN 188 for the Treatment of Migraine With Aura
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZECUITY FDA Label Details

View full patent landscape →
9 OB patents · 5 families · 143 international docs across 15 countries

ZECUITY Patents & Exclusivity

Latest Patent: Oct 2032

Patents (9 active)

US9327114 Expires Oct 8, 2032
US8983594 Expires Nov 19, 2030
US8366600 Expires Apr 21, 2029
US9272137 Expires Sep 7, 2027
US7973058 Expires Apr 12, 2027
US8155737 Expires Apr 12, 2027
US8470853 Expires Apr 12, 2027
US9427578 Expires Apr 12, 2027
US8597272 Expires Apr 12, 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ZECUITY

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2032
  • 9 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.